Ravulizumab治疗IgA肾病——一项3期试验的中期分析
完整摘要 · 中文译文
背景:在IgA肾病患者中,补体激活驱动肾小球炎症,从而导致血尿、蛋白尿和肾单位丢失。Ravulizumab是一种终末补体抑制剂,可阻止C5a和C5b-9的形成。 方法:在这项3期试验中,我们纳入了尽管接受标准治疗但仍存在估算肾小球滤过率至少为每分钟每1.73 m2体表面积30 ml且蛋白尿(24小时尿蛋白与肌酐比值[蛋白和肌酐均以克计]≥0.75或每日总尿蛋白排泄量≥1.0 g)的成人IgA肾病患者。患者按1:1比例随机分配,每8周接受一次ravulizumab或安慰剂静脉输注。在预设的中期分析中,主要疗效终点为第34周时24小时尿蛋白与肌酐比值较基线的变化。同时评估了安全性。 结果:共有485例患者接受了随机分组,其中240例被分配至ravulizumab组,245例被分配至安慰剂组;352例患者(每组各176例)被纳入中期分析。ravulizumab组基线和第34周时的24小时尿蛋白与肌酐比值几何均值分别为1.56和0.83;安慰剂组分别为1.60和1.48。第34周时,与安慰剂组观察到的降幅(-5.6%)相比,ravulizumab组的24小时尿蛋白与肌酐比值几何均值降幅显著(-46.6%),相当于ravulizumab组经校正的24小时尿蛋白与肌酐比值几何均值较安慰剂组低43.4%(99%置信区间,30.1至54.2)(P<0.001)。接受ravulizumab治疗的患者中69.5%发生不良事件,接受安慰剂治疗的患者中75.8%发生不良事件;严重不良事件分别发生于4.6%和9.0%的患者。未发生脑膜炎球菌感染或死亡。 结论:在成人IgA肾病(IgA nephropathy)患者中,ravulizumab在第34周时使蛋白与肌酐比值较安慰剂组出现显著更大的降幅。(由Alexion,AstraZeneca Rare Disease Unit资助;I CAN ClinicalTrials.gov注册号,NCT06291376;EU Clinical Trials注册号,2023-507851-31-00。)
完整摘要 · 英文原文
BACKGROUND: In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss. Ravulizumab is a terminal complement inhibitor that prevents formation of C5a and C5b-9. METHODS: In this phase 3 trial, we enrolled adults with IgA nephropathy who had an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area and proteinuria (24-hour urinary protein-to-creatinine ratio [with protein and creatinine both measured in grams] of ≥0.75 or total urinary protein excretion of ≥1.0 g per day), despite standard therapy. Patients were randomly assigned in a 1:1 ratio to receive an intravenous infusion of either ravulizumab or placebo every 8 weeks. In the prespecified interim analysis, the primary efficacy end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34. Safety was also assessed. RESULTS: In all, 485 patients underwent randomization, with 240 patients assigned to the ravulizumab group and 245 to the placebo group; 352 patients (176 in each group) were included in the interim analysis. In the ravulizumab group, the geometric mean 24-hour urinary protein-to-creatinine ratio at baseline and at week 34 was 1.56 and 0.83, respectively; in the placebo group, it was 1.60 and 1.48, respectively. At week 34, a significant reduction in the geometric mean 24-hour urinary protein-to-creatinine ratio was observed with ravulizumab (-46.6%) as compared with the reduction observed with placebo (-5.6%), corresponding to an adjusted geometric mean 24-hour urinary protein-to-creatinine ratio that was 43.4% (99% confidence interval, 30.1 to 54.2) lower with ravulizumab than with placebo (P<0.001). Adverse events occurred in 69.5% of the patients receiving ravulizumab and in 75.8% of those receiving placebo; serious adverse events occurred in 4.6% and 9.0%, respectively. No meningococcal infections or deaths occurred. CONCLUSIONS: In adults with IgA nephropathy, ravulizumab resulted in a significantly greater reduction in the protein-to-creatinine ratio than placebo at week 34. (Funded by Alexion, AstraZeneca Rare Disease Unit; I CAN ClinicalTrials.gov number, NCT06291376; EU Clinical Trials number, 2023-507851-31-00.).